ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

Officials: Poisoning Unrelated to MD Anderson; Critics Allege Dysfunction in Handling of Affair

September 19, 2014

Gori to Hopkins Part Time, Keeps DCCP Deputy Job

September 1, 1978

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

August 2, 1991

Guest Editorial: Richard Schilsky Reflects On His Past Decade WithThe Board of Scientific Advisors

June 24, 2011

FDA to refer false statements by regulated companies to SEC.

February 27, 2004

PSA Velocity Poor Predictor Of Prostate Cancer Occurrence

March 25, 2011